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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
14.05.2020 The association 
of 
cardiovascular 
disease and 
other pre-
existing co-
morbidities with 
COVID-19 
mortality: A 
systematic 
review and 
meta-analysis 
medRxiv preprint 
(not peer 
reviewed) | 
Systematic 
review and meta-
analysis 
 Ten chronic conditions from 
19 studies were included in 
the meta-analysis 
 COVID-19 patients with any 
cardiovascular disease, 
coronary heart disease, 
hypertension, congestive 
heart failure, ad cancer have 
a significantly increased risk 
of mortality 
12.05.2020 Manifestations 
and prognosis of 
gastrointestinal 
and liver 
involvement in 
patients with 
COVID-19: a 
systematic 
The Lancet 
Gastroenterology 
& Hepatology | 
Systematic 
review and meta-
analysis 
 Digestive symptoms and liver 
injury are not uncommon in 
patients with COVID-19 
 Approximately 10% of 
patients with COVDI-19 might 
present with gastrointestinal 
symptoms only, without 
respiratory symptoms 
2 
review and 
meta-analysis 
 Patients with severe COVID-
19 had a higher risk of 
developing gastrointestinal 
symptoms and liver injury 
compared to patients with 
non-severe disease 
 Patients with digestive 
system involvement as initial 
symptoms have delayed 
diagnosis of COVID-19, and 
those with digestive 
involvement tend to progress 
to severe or critical disease  
 Children had a similar 
prevalence of gastrointestinal 
symptoms to adults with 
COVID-19 
13.05.2020 An outbreak of 
severe 
Kawasaki-like 
disease at the 
Italian epicentre 
of the SARS-
CoV-2 epidemic: 
an observational 
cohort study 
The Lancet | 
Article 
 In the Bergamo province in 
Italy, a 30-fold increased 
incidence of Kawasaki-like 
disease was found in the past 
month 
 Children diagnosed after the 
SARS-CoV-2 epidemic began 
showed evidence of immune 
response to the virus, were 
older, had a higher rate of 
cardiac involvement, and 
features of MAS. 
 SARS-CoV-2 was associated 
with high incidence of a 
severe form of Kawasaki 
disease 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
07.05.2020 Projected 
early 
spread of 
COVID-19 
in Africa 
through 1 
June 2020 
Euro Surveill. | 
Rapid 
Communication 
 Estimates of the date of reporting 
1,000 and 10,000 COVID-19 cases 
for 45 African countries/territories 
already reporting COVID-19 cases 
before 23 March 2020 are projected 
 All 45 countries were likely to 
exceed 1,000 confirmed cases by 
the end of April 2020, with most 
3 
exceeding 10,000 a few weeks 
later, assuming early epidemic 
trends with reported cases lagging 
and under-representing actual 
burden 
 Projections assumed no substantive 
changes between the initially 
reported cases and forecast points 
– whilst some countries have taken 
drastic actions impacting on these 
assumptions, others have not or 
acted slowly 
Testing 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
13.05.2020 Variation in 
false-
negative rate 
of reverse 
transcriptase 
polymerase 
chain 
reaction-
based 
SARS-CoV-2 
tests by time 
since 
exposure 
Annals of 
Internal 
Medicine | 
Article 
 This study estimates the false-
negative rate of RT-PCR tests for 
SARS-CoV-2 by day since 
exposure and symptom onset from 
7 studies with a total of 1330 
respiratory samples analysed by 
RT-PRC 
 Over the 4 days of infection before 
typical show of symptoms, the 
probability of a false-negative 
result in an infected person 
decreased from 100% on day 1 to 
68% on day 4 
 On the day of symptom onset the 
probability of a false-negative 
result in an infected person was 
38% decreasing to 20% on day 8 
(3 days after symptom onset) and 
increasing again from 21% on day 
9 to 66% on day 21 
 Optimal time for testing may be 
during a window period of 3 to 5 
days after the onset of symptoms 
to minimise false-negative results 
 Care must be taken to interpret 
RT-PCR test results for SARS-
CoV-2 in the context of the clinical 
and epidemiological situation to 
avoid being falsely reassured by 
4 
negative test results, particularly 
early in the course of infection 
 This is critical as decisions are 
made about whether to stop using 
PPE and HCW return to work 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
12.05.2020 Identification 
of falsified 
chloroquine 
tablets in 
Africa at the 
time of the 
COVID-19 
pandemic 
Am J Trop 
Med Hyg | 
Article 
 Five different types of falsified 
chloroquine tablets were 
discovered between 31 March and 
4 April 2020 in Cameroon and 
DRC by locally conducted thin 
layer chromatographic analysis 
 Absence or reduced amounts of 
chloroquine and the presence of 
undeclared active pharmaceutical 
ingredients, paracetamol and 
metronidazole, were confirmed by 
subsequent investigation by liquid 
chromatography and mass 
spectrometry in Germany 
 Highlights the need for timely 
preparations for the detection of 
falsified therapeutics against 
COVID-19, including establishing 
screening technologies in LMICs 
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
13.05.2020 ChAdOx1 
nCoV-19 
vaccination 
prevents 
SARS-CoV-
2 
pneumonia 
in rhesus 
macques 
bioRxiv 
preprint (not 
peer 
reviewed) | 
Article 
 This study shows that the 
adenovirus-vectored vaccine 
ChAdOx1 nCoV-19, encoding the 
spike protein of SARS-CoV-2, 
induced a humoral and cell-
mediated response in mice 
 Also a single vaccination with 
ChAdOx1 nCoV-19 induced a 
humoral and cell-mediated 
response in rhesus macaques 
5 
 A significantly reduced viral load 
was observed in bronchoalveolar 
lavage fluid and respiratory tract 
tissue of vaccinated animals 
challenged with SARS-CoV-2 
compared with control animals and 
no pneumonia was observed in 
vaccinated rhesus macaques 
 No evidence of immune-enhanced 
disease following viral challenge 
was observed 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
12.05.2020 Equity in 
response to 
the COVID-19 
pandemic: an 
assessment of 
the direct and 
indirect 
impacts on 
disadvantaged 
and vulnerable 
populations in 
low- and 
lower-middle-
income 
countries 
Imperial 
College 
London 
COVID-19 
response 
team | Report 
22 
 A COVID-19 transmission model 
was used to explore health 
inequities using large-scale 
household surveys to quantify the 
differences in handwashing 
access, occupation and hospital 
access with respect to wealth 
status in low-income settings 
 Results clearly show a trend that 
the probability of death from 
COVID-19 increases with 
increasing poverty 
 On average, a 32.0% (2.5th-97.5th 
centile 8.0-72.5%) estimate 
increase in the probability of 
death in the poorest quintile 
compared to the wealthiest 
quintile from the three factors 
listed above alone 
 Vulnerable and disadvantaged 
populations are at greater risk of 
both the direct impact of COVID-
19 (e.g. morbidity and mortality) 
and indirect impact (e.g. food 
security and loss of livelihoods) 
  
6 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
06.05.2020 Simple ideas to mitigate the 
impacts of the COVID-19 
epidemic on refugees with 
chronic diseases 
Conflict and Health | 
Letter to the Editor 
Muhammad 
Fawad 
Fatima 
Rawashdeh  
Parveen K. 
Parmar 
Ruwan Ratnayake 
12.05.20 The fight to end tuberculosis 
must not be forgotten in the 
COVID-19 outbreak 
Nature Medicine | 
Correspondence 
Tsegahun 
Manyazewal 
Yimtubezinash 
Woldeamanuel 
Henrey M. 
Blumberg 
Abebaw Fekadu 
Vincent C. 
Marconi  
01.05.2020 Monitoring the COVID-19 
pandemic in sub-Saharan Africa: 
focusing on health facility 
admissions and deaths 
IJTLD | 
Correspondence 
A.D. Harries 
L. Martinez 
J.M. Chakaya 
01.05.2020 Tackling the threat of COVID-19 
in Africa: an urgent need for 
practical planning 
IJTLD | 
Correspondence 
C-Y Chiang 
A El Sony  
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Dashboards & Trackers 
Cases & 
deaths: 
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evidence 
& policy 
maps 
Current 
research 
including trials 
  Diagnosti
cs 
  Treatment
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WHO 
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WHO 
Africa 
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WHO   FIND 
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CoV-2 Test 
Tracker 
  Global 
COVID-19 
Clinical 
Trial 
Tracker 
  CEPI 
WHO 
dashboard 
African 
Argumen
ts 
Indonesi
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EPPI 
Centre 
WHO 
International 
Clinical Trials 
Registry 
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 FIND 
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CoV-2 
Diagnostic
s: 
performanc
e data 
  US NIH 
registered 
clinical 
trials 
Vaccine 
Centre 
LSHTM 
Johns 
Hopkins 
University 
Europea
n CDC 
Nigeria 
CDC 
Norwegian 
Institute of 
Public 
Health 
Cytel  Serology-
based 
tests for 
COVID-19 
  Solidarity 
trial 
 COVID-
19 
Oxford 
Vaccine 
Trial 
WEF 
  Sierra 
Leone 
 Oxford 
C19 
Governme
nt 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World 
in Data: 
C19 
Testing 
  COVID-
19 
Therapeuti
cs 
Accelerator 
  
Our World 
in Data 
  Singapor
e 
 Our World 
in Data: 
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COVID-
evidence 
      
Global 
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8 
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CDC 
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  Disability 
and 
inclusion 
9 
WHO Global 
research 
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: SSA 
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resource 
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Fund 
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Press 
Johns Hopkins University 
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Science
s 
Cochran
e 
resource
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Development 
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 Evidence Aid     
10 
GOARN      NIH     
EPI-WIN           
World Bank           
Our World in 
Data 
          
COVID-19 
Narratives by 
David 
Nabarro 
          
Reliefweb           
Humanitarian 
OpenStreetM
ap Team 
          
Global 
Partnership 
for 
Sustainable 
Development 
Data 
          
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global Impact 
Study 
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Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
12 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
13 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
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